FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806321321> ?p ?o ?g. }

• W2806321321 endingPage "67" @default.
• W2806321321 startingPage "54" @default.
• W2806321321 abstract "Emerging Oral Medications for Multiple Sclerosis Other therapeutics in the pipeline and future directionsYuval Karmon, Bijal Mehta & Bianca Weinstock-GuttmanYuval KarmonYuval Karmon is a Neurologist specializing in Multiple Sclerosis at the Baird MS center at the Jacobs Neurological Institute, State University of New York at Buffalo (NY, USA). He also completed an Endovascular Stroke Research fellowship at the University at Buffalo Neurosurgery Department.Search for more papers by this author, Bijal MehtaBijal K Mehta is an Assistant Clinical Professor of Neurology, State University of New York at Buffalo, Department of Neurology, Jacobs Neurological Institute Buffalo (NY, USA).Search for more papers by this author & Bianca Weinstock-GuttmanBianca Weinstock-Guttman is Professor of Neurology, State University of New York at Buffalo (NY, USA), Director of the Baird MS Center at The Jacobs Neurological Institute (NY, USA) and the Executive director of the NY State MS Consortium (NY, USA). She is also Director of the Pediatric MS Center of the Jacobs Neurological Institute, one of six centers of excellence established by the National MS Society.Search for more papers by this authorPublished Online:15 Mar 2012https://doi.org/10.2217/ebo.12.37AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInReddit View chapterAbstract: For the last two decades since the first specific treatments became available to treat multiple sclerosis, there has been acceleration in the development of new and more highly effective disease-modifying drugs. New monoclonal therapies have been tested and have already received regulatory approval or showed therapeutic benefits in Phase III multicenter studies. None of these therapies appear to be curative, and most target primarily the inflammatory stage of the disease and its consequences. Therefore, there is ongoing exploration of novel interventions that may more completely control both the inflammatory and neurodegenerative components of multiple sclerosis. This chapter will provide an overview of the most recent studies on some experimental oral medications not yet approved for clinical use, aimed at re-establishing immune tolerance in multiple sclerosis (MS). We will also discuss some oral agents available with other indications that are explored for their possible beneficial effects in MS, including statins, vitamin D and estriol. Recent approved symptomatic specific therapies that may improve MS patient quality of life and functionality will be also presented. References1 Kapoor R , Furby J , Hayton T et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial . Lancet Neurol. 9 (7) , 681 – 688 (2010) . Crossref, Medline, CAS, Google Scholar2 Barkhof F , Hulst HE , Drulovic J , Uitdehaag BM , Matsuda K , Landin R . Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74 (13) , 1033 – 1040 (2010) . Crossref, Medline, CAS, Google Scholar3 Huang JK , Jarjour AA , Nait Oumesmar B et al. Retinoid X receptor gamma signaling accelerates CNS remyelination . Nat. Neurosci. 14 (1) , 45 – 53 (2011) . Crossref, Medline, CAS, Google Scholar4 Gold SM , Voskuhl RR . Estrogen and testosterone therapies in multiple sclerosis . Prog. Brain. Res. 175 , 239 – 251 (2009) . Crossref, Medline, CAS, Google Scholar5 Sicotte NL , Liva SM , Klutch R et al. Treatment of multiple sclerosis with the pregnancy hormone estriol . Ann. Neurol. 52 (4) , 421 – 428 (2002) . Crossref, Medline, CAS, Google Scholar6 Yong VW , Wells J , Giuliani F , Casha S , Power C , Metz LM . The promise of minocycline in neurology . Lancet Neurol. 3 (12) , 744 – 751 (2004) . Crossref, Medline, Google Scholar7 Metz LM , Li D , Traboulsee A et al. Glatiramer acetate in combination with minocycline in patients with relapsing–remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial . Multiple sclerosis 15 (10) , 1183 – 1194 (2009) . Crossref, Medline, CAS, Google Scholar8 Willey JZ , Elkind MS . 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases . Arch. Neurol. 67 (9) , 1062 – 1067 (2010) . Crossref, Medline, Google Scholar9 Sellner J , Weber MS , Vollmar P , Mattle HP , Hemmer B , Stuve O . The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon? CNS Neurosci. Ther. 16 (6) , 362 – 373 (2010) . Crossref, Medline, CAS, Google Scholar10 Atkins H . Hematopoietic SCT for the treatment of multiple sclerosis . Bone Marrow Transplant 45 (12) , 1671 – 1681 (2010) . Crossref, Medline, CAS, Google Scholar11 Rudick RA , Pace A , Rani MR et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a . Neurology 72 (23) , 1989 – 1993 (2009) . Crossref, Medline, CAS, Google Scholar12 Waubant E PD , Mass M et al. Atorvastatin therapy in patients with Clinically Isolated Syndrome (CIS): the STAyCIS study . Neurology (2011) (In press) . Google Scholar13 Klopfleisch S , Merkler D , Schmitz M et al. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo . J. Neurosci. 28 (50) , 13609 – 13614 (2008) . Crossref, Medline, CAS, Google Scholar14 Markovic-Plese S , Jewells V , Speer D . Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis . Neurology 72 (22) , 65 – 66 (2009) . Google Scholar15 Sorensen PS LJ , Erälinna JP , Edland A et al. for the SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised Phase 4 trial . Lancet Neurol. 10 (8) , 691 – 701 (2011) . Crossref, Medline, Google Scholar16 Lucas RM , Ponsonby AL , Dear K et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination . Neurology 76 (6) , 540 – 548 (2011) . Crossref, Medline, CAS, Google Scholar17 Munger KL , Levin LI , Hollis BW , Howard NS , Ascherio A . Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis . JAMA 296 (23) , 2832 – 2838 (2006) . Crossref, Medline, CAS, Google Scholar18 Simpson S , Taylor B , Blizzard L et al. Higher 25-hydroxy vitamin D is associated with lower relapse risk in multiple sclerosis . Ann. Neurol. 68 (2) , 193 – 203 (2010) . Medline, CAS, Google Scholar19 Weinstock-Guttman B , Zivadinov R , Qu J et al. Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients . J. Neurol. Neurosurg. Psychiatry 82 (2) , 189 – 195 (2011) . Crossref, Medline, Google Scholar20 Wingerchuk DM , Lesaux J , Rice GP , Kremenchutzky M , Ebers GC . A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis . J. Neurol. Neurosurg. Psychiatry 76 (9) , 1294 – 1296 (2005) . Crossref, Medline, CAS, Google Scholar21 Burton JM , Kimball S , Vieth R et al. A Phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis . Neurology 74 (23) , 1852 – 1859 (2010) . Crossref, Medline, CAS, Google Scholar22 Millard M , Odde S , Neamati N . Integrin targeted therapeutics . Theranostics 1 , 154 – 188 (2011) . Crossref, Medline, CAS, Google Scholar23 Sheremata WA , Vollmer TL , Stone LA , Willmer-Hulme AJ , Koller M . A safety and pharmacokinetic study of intravenous natalizumab in patients with MS . Neurology 52 (5) , 1072 – 1074 (1999) . Crossref, Medline, CAS, Google Scholar24 Miller D WT , Montalban X , Grove R , Dua P , Wardell C , Graff O . Phase II trial of firategrast shows that oral anti-alpha4 therapy can suppress new MRI lesions in relapsing–remitting multiple sclerosis. Multiple sclerosis. ECTRIMS 2010. Gothenburg, Sweden, 2010 . Google Scholar25 Miller DH , Weber T , Grove R et al. Firategrast for relapsing remitting multiple sclerosis: a Phase 2, randomised, double-blind, placebo-controlled trial . Lancet Neurol. 11 (2) , 131 – 139 (2012) . Crossref, Medline, CAS, Google Scholar26 Kocsis JD , Bowe CM , Waxman SG . Different effects of 4-aminopyridine on sensory and motor fibers: pathogenesis of paresthesias . Neurology 36 (1) , 117 – 120 (1986) . Crossref, Medline, CAS, Google Scholar27 Schafer EW , Brunton RB , Cunningham DJ . A summary of the acute toxicity of 4-aminopyridine to birds and mammals . Toxicol. Appl. Pharmacol. 26 (4) , 532 – 538 (1973) . Crossref, Medline, CAS, Google Scholar28 Sherratt RM , Bostock H , Sears TA . Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres . Nature 283 (5747) , 570 – 572 (1980) . Crossref, Medline, CAS, Google Scholar29 Ampyra®, package insert. Acorda Therapeutics, Inc, NY, USA . Google Scholar30 Goodman AD , Brown TR , Edwards KR et al. A Phase 3 trial of extended release oral dalfampridine in multiple sclerosis . Ann. Neurol. 68 (4) , 494 – 502 (2010) . Crossref, Medline, CAS, Google Scholar31 Goodman AD , Brown TR , Krupp LB et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial . Lancet 373 (9665) , 732 – 738 (2009) . Crossref, Medline, CAS, Google Scholar32 Chwieduk CM , Keating GM . Dalfampridine extended release: in multiple sclerosis . CNS Drugs 24 (10) , 883 – 891 (2010) . Crossref, Medline, CAS, Google Scholar33 Polman CH , Bertelsmann FW , van Loenen AC , Koetsier JC . 4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety . Arch. Neurol. 51 (3) , 292 – 296 (1994) . Crossref, Medline, CAS, Google Scholar34 FDA Administration. Briefing Information. Presented at: Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; NDA 22–250: Fampridine Advisory Committee Backgrounder. 14 October 2009 . Google Scholar35 Beard S , Hunn A , Wight J . Treatments for spasticity and pain in multiple sclerosis: a systematic review . Health Technol. Assess 7 (40) , iii , ix–x , 111–111 (2003) . Medline, CAS, Google Scholar36 Baker D , Pryce G , Croxford JL et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model . Nature 404 (6773) , 84 – 87 (2000) . Crossref, Medline, CAS, Google Scholar37 Zajicek J , Fox P , Sanders H et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial . Lancet 362 (9395) , 1517 – 1526 (2003) . Crossref, Medline, CAS, Google Scholar38 Zajicek JP , Sanders HP , Wright DE et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up . J. Neurol. Neurosurg. Psychiatry 76 (12) , 1664 – 1669 (2005) . Crossref, Medline, CAS, Google Scholar39 Collin C , Davies P , Mutiboko IK , Ratcliffe S . Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis . Eur. J. Neurol. 14 (3) , 290 – 296 (2007) . Crossref, Medline, CAS, Google Scholar40 Collin C , Ehler E , Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis . Neurol. Res. 32 (5) , 451 – 459 (2010) . Crossref, Medline, CAS, Google Scholar41 Novotna A , Mares J , Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis . Eur. J. Neurol. 18 (9) , 1122 – 1131 (2011) . Crossref, Medline, CAS, Google Scholar42 Hobart JC , Riazi A , Thompson AJ et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88) . Brain 129 (Pt 1) , 224 – 234 (2006) . Crossref, Medline, CAS, Google Scholar43 Wade DT , Collin C , Stott C , Duncombe P . Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis . Mult. Scler. 16 (6) , 707 – 714 (2010) . Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Emerging Oral Medications for Multiple SclerosisMetrics Downloaded 5 times History Published online 15 March 2012 Published in print March 2012 Information© Future Medicine Ltd© Future Medicine LtdPDF download" @default.
• W2806321321 created "2018-06-13" @default.
• W2806321321 creator A5006794634 @default.
• W2806321321 creator A5026688054 @default.
• W2806321321 creator A5075596287 @default.
• W2806321321 date "2012-03-01" @default.
• W2806321321 modified "2023-10-17" @default.
• W2806321321 title "Other therapeutics in the pipeline and future directions" @default.
• W2806321321 cites W1495176512 @default.
• W2806321321 cites W1732676806 @default.
• W2806321321 cites W1790460690 @default.
• W2806321321 cites W1801725150 @default.
• W2806321321 cites W1965452646 @default.
• W2806321321 cites W1996607415 @default.
• W2806321321 cites W2028313592 @default.
• W2806321321 cites W2031114852 @default.
• W2806321321 cites W2043053000 @default.
• W2806321321 cites W2045167317 @default.
• W2806321321 cites W2061238254 @default.
• W2806321321 cites W2063885093 @default.
• W2806321321 cites W2065835036 @default.
• W2806321321 cites W2066749493 @default.
• W2806321321 cites W2075298115 @default.
• W2806321321 cites W2084404808 @default.
• W2806321321 cites W2086344593 @default.
• W2806321321 cites W2096967123 @default.
• W2806321321 cites W2106185842 @default.
• W2806321321 cites W2121887429 @default.
• W2806321321 cites W2126574528 @default.
• W2806321321 cites W2135123671 @default.
• W2806321321 cites W2135551891 @default.
• W2806321321 cites W2136411200 @default.
• W2806321321 cites W2137424771 @default.
• W2806321321 cites W2140180096 @default.
• W2806321321 cites W2145016172 @default.
• W2806321321 cites W2145583517 @default.
• W2806321321 cites W2149218665 @default.
• W2806321321 cites W2155356695 @default.
• W2806321321 cites W2157845677 @default.
• W2806321321 cites W2158402891 @default.
• W2806321321 cites W2167664390 @default.
• W2806321321 cites W2171143812 @default.
• W2806321321 cites W2271403228 @default.
• W2806321321 doi "https://doi.org/10.2217/ebo.12.37" @default.
• W2806321321 hasPublicationYear "2012" @default.
• W2806321321 type Work @default.
• W2806321321 sameAs 2806321321 @default.
• W2806321321 citedByCount "0" @default.
• W2806321321 crossrefType "other" @default.
• W2806321321 hasAuthorship W2806321321A5006794634 @default.
• W2806321321 hasAuthorship W2806321321A5026688054 @default.
• W2806321321 hasAuthorship W2806321321A5075596287 @default.
• W2806321321 hasConcept C199360897 @default.
• W2806321321 hasConcept C41008148 @default.
• W2806321321 hasConcept C43521106 @default.
• W2806321321 hasConcept C70721500 @default.
• W2806321321 hasConcept C86803240 @default.
• W2806321321 hasConceptScore W2806321321C199360897 @default.
• W2806321321 hasConceptScore W2806321321C41008148 @default.
• W2806321321 hasConceptScore W2806321321C43521106 @default.
• W2806321321 hasConceptScore W2806321321C70721500 @default.
• W2806321321 hasConceptScore W2806321321C86803240 @default.
• W2806321321 hasLocation W28063213211 @default.
• W2806321321 hasOpenAccess W2806321321 @default.
• W2806321321 hasPrimaryLocation W28063213211 @default.
• W2806321321 hasRelatedWork W1557184149 @default.
• W2806321321 hasRelatedWork W2039534605 @default.
• W2806321321 hasRelatedWork W2051963567 @default.
• W2806321321 hasRelatedWork W2360883279 @default.
• W2806321321 hasRelatedWork W2560284304 @default.
• W2806321321 hasRelatedWork W259064346 @default.
• W2806321321 hasRelatedWork W2591599309 @default.
• W2806321321 hasRelatedWork W2992516105 @default.
• W2806321321 hasRelatedWork W3120899676 @default.
• W2806321321 hasRelatedWork W3210635025 @default.
• W2806321321 isParatext "false" @default.
• W2806321321 isRetracted "false" @default.
• W2806321321 magId "2806321321" @default.
• W2806321321 workType "other" @default.